Tags: US | Merck | Afferent | Purchase

Merck to Buy Biotech Drug Developer Afferent Pharmaceuticals

Friday, 10 Jun 2016 07:00 AM

Drugmaker Merck is buying Afferent Pharmaceuticals, a privately held biotechnology company developing a chronic cough medication.

Merck & Co., based in Kenilworth, New Jersey, says it's agreed to pay $500 million up front for Afferent, and up to $750 million more if the company meets goals for approval and eventual sales of medicines in development.

Afferent, based in San Mateo, California, focuses on creating treatments for "neurogenic conditions" — health problems caused when certain nerves become hypersensitive, for months or years, following an infection, injury or inflammation. Those conditions, affecting millions of people, include chronic pain and respiratory, cardiovascular and urologic disorders.

Afferent's medicine furthest along in development, known as AF-219, is in mid-stage human testing for treating coughs lasting more than eight weeks that don't respond to existing treatments.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

 
1Like our page
2Share
Companies
Drugmaker Merck is buying Afferent Pharmaceuticals, a privately held biotechnology company developing a chronic cough medication.
US, Merck, Afferent, Purchase
129
2016-00-10
Friday, 10 Jun 2016 07:00 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved